Work Here?
BillionToOne
Work Here?
QCT-based molecular diagnostics for prenatal, oncology
BillionToOne
Work Here?
QCT-based molecular diagnostics for prenatal, oncology
Overview
BillionToOne provides molecular diagnostic testing for prenatal screening and cancer monitoring. Its QCT technology detects and measures DNA variations at a single base-pair level, enabling precise analysis across the three billion DNA letters. The main products, Northstar Select and Northstar Response, are tests that help doctors choose the best first-line therapy and track how well treatment is working, respectively. The company markets these services to healthcare providers who perform the tests and use the results to guide patient care. Unlike some rivals, BillionToOne emphasizes high-resolution DNA assessment and scalable diagnostic services through provider partnerships, aiming to improve accuracy, speed, and access. Its mission is to make molecular testing more accurate, efficient, and accessible to all, driven by growth, equality, and teamwork.
About BillionToOne
Industries
Biotechnology
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
Menlo Park, California
Founded
2016
Get referred to BillionToOne
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $109.4 million, up 64%, with positive operating income.
- Oncology revenue jumped 176% in Q2 2026 after Northstar Select and Response expansion.
- Management reaffirmed 2026 revenue guidance of $450 million to $465 million, signaling execution confidence.
What critics are saying
- Illumina sued BillionToOne on May 7, 2026 over prenatal-test patent infringement.
- Prenatal pricing depends on reimbursement; any payer pushback hits the $94.2 million franchise.
- Competitors like Natera and Guardant can outspend BillionToOne on sales and evidence.
What makes BillionToOne unique
- Unity Complete and Northstar use single-molecule cfDNA counting for rare-variant detection.
- August 17, 2026 launched 130-gene fetal panel, the largest single-gene NIPT panel.
- September 1, 2026 Northstar Origin added tissue-of-origin prediction without extra blood draws.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$699.1M
Above
Industry Average
Funded Over
10 Rounds
Y CombinatorBenefits
Competitive pay
Retirement savings package
Parental leave
Free snacks & lunches
Medical, dental, & vision premiums
On campus perks
Free-on-site EV charging
Stock Price
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 0%2 year growth
↑ 0%BillionToOne has launched Northstar Origin, a liquid biopsy add-on test that predicts tissue of origin from circulating cell-free DNA for patients with cancer of unknown primary or uncertain cancer diagnosis. The test requires no additional tissue or separate blood draws beyond what's already collected for therapy selection. In a validation study of 1,578 patients, Northstar Origin identified the correct tissue of origin as its top prediction in 87% of cases and within its top three predictions in 91% of cases. The classifier was developed using 6,025 blood samples from advanced cancer patients. The company also expanded its Northstar Select panel from 84 to 102 genes, adding 18 new genes including MTAP deletion. The test is designed to help community oncologists make diagnostic decisions, as roughly 3-5% of new cancer diagnoses present as cancer of unknown primary.
David Tsao, co-founder and chief technology officer of BillionToOne, sold 10,000 shares of Class A Common Stock for $1 million on 25 August 2026. The transaction involved a cashless exercise of fully vested stock options at $2.80 per share, with the resulting shares sold at a weighted average price of $100. The sale was executed under a Rule 10b5-1 trading plan adopted in March 2026, indicating it was pre-scheduled rather than discretionary. Tsao retains 1,000 direct shares and 580,000 stock options. BillionToOne, a Menlo Park-based molecular diagnostics company, reported second-quarter revenue of $109.4 million, representing 64% year-over-year growth. The company has a market capitalisation of $4.4 billion and generated $397.4 million in trailing 12-month revenue with $33.5 million in net income.
BillionToOne, a molecular diagnostics company, reported second-quarter 2026 revenue of $109.4 million, up 64% from $66.6 million in the same period last year. Prenatal clinical testing revenue reached $94.2 million, whilst oncology testing revenue surged 176% to $13.7 million. The company delivered 196,000 tests during the quarter, a 35% increase year-over-year. Gross profit margin improved to 70% from 65%. BillionToOne posted operating income of $5.5 million, compared to a $1.6 million loss in Q2 2025. The firm reiterated its full-year 2026 revenue guidance of $450 million to $465 million, representing 48% to 52% growth over 2025. BillionToOne announced plans to expand its Unity Fetal Risk Screen with a 130-gene panel launching 17 August 2026.
BillionToOne reported strong second-quarter results for 2026, with total revenue reaching $109.4 million, up 64% year-over-year. Prenatal revenue rose 56% to $95.8 million, while oncology revenue surged 176% to $13.7 million. The company achieved gross margins of 70.5%, up 5 percentage points from the previous year. BillionToOne posted operating income of $5.5 million and net income of $8.1 million, or $0.15 per diluted share. Test volumes increased 35% year-over-year to approximately 196,000 tests, with average selling prices rising 21% to $551 per test. The company generated $9.1 million in cash from operations and $5.1 million in free cash flow. BillionToOne maintained its full-year 2026 revenue guidance of $450 million to $465 million.
BillionToOne to launch NIPT, liquid biopsy add-ons as Q2 revenue rises 64 percent. NEW YORK - BillionToOne said on Wednesday that its second-quarter revenue grew 64 percent year over year on the back of strong prenatal and oncology clinical testing sales. Get the full story with GenomeWeb Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month Already a GenomeWeb member? LoginLogin
BillionToOne is Hiring for 82 Jobs on Simplify!
Find jobs on Simplify and start your career today
About BillionToOne
Industries
Biotechnology
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
Menlo Park, California
Founded
2016
BillionToOne is Hiring for 82 Jobs on Simplify!
Find jobs on Simplify and start your career today